Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v2-FR
Language English French
Date Updated 2023-01-17 2022-11-01
Drug Identification Number 02505134 02505134
Brand name EMGALITY EMGALITY
Common or Proper name galcanezumab injection galcanezumab injection
Company Name ELI LILLY CANADA INC ELI LILLY CANADA INC
Ingredients GALCANEZUMAB GALCANEZUMAB
Strength(s) 100MG 100MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size Carton package containing three 100 mg/mL prefilled syringes Carton package containing three 100 mg/mL prefilled syringes
ATC code N02CD N02CD
ATC description
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-10-27 2022-10-27
Estimated end date 2023-01-16 2023-01-16
Actual end date 2023-01-16
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Health Canada comments